You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

Genus Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Genus
International Patents:45
US Patents:7
Tradenames:27
Ingredients:25
NDAs:34

Drugs and US Patents for Genus

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-007 Jun 6, 2003 AB1,AB2,AB3,AB4 RX No No 10,231,931 ⤷  Try for Free Y ⤷  Try for Free
Genus HYDROCODONE BITARTRATE AND ACETAMINOPHEN acetaminophen; hydrocodone bitartrate SOLUTION;ORAL 200343-001 Jan 25, 2012 DISCN No No ⤷  Try for Free ⤷  Try for Free
Genus ISONIAZID isoniazid TABLET;ORAL 080936-001 Approved Prior to Jan 1, 1982 AA RX No Yes ⤷  Try for Free ⤷  Try for Free
Genus CLEMASTINE FUMARATE clemastine fumarate SYRUP;ORAL 073399-001 Jun 30, 1994 AA RX No Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Genus

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 6,926,907 ⤷  Try for Free
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 6,926,907 ⤷  Try for Free
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 9,364,439 ⤷  Try for Free
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 8,206,741 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for GENUS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 81 mg/40 mg ➤ Subscribe 2016-10-14

Supplementary Protection Certificates for Genus Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3141251 301099 Netherlands ⤷  Try for Free PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
0480717 98C0025 Belgium ⤷  Try for Free PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
1441735 SPC/GB08/020 United Kingdom ⤷  Try for Free PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
1534313 92923 Luxembourg ⤷  Try for Free PRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Genus – Market Position, Strengths & Strategic Insights

Last updated: February 12, 2025

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Today, we'll dive deep into Genus, a unique player in the animal genetics sector, examining its market position, strengths, and strategic insights. This analysis will provide valuable information for industry professionals, investors, and anyone interested in the intersection of biotechnology and agriculture.

Genus: A Leader in Animal Genetics

Genus plc is a global leader in animal genetics, specializing in porcine and bovine genetic improvement[1]. The company's mission is to pioneer animal genetic improvement to sustainably nourish the world[10]. This unique positioning sets Genus apart in the pharmaceutical and biotechnology sectors.

Core Business and Market Reach

Genus operates through two primary brands:

  1. ABS: Focused on dairy and beef cattle genetics
  2. PIC: Specializing in pig genetics

The company's products and services are available in over 80 countries, demonstrating its global reach and influence[10]. Genus serves many of the Top 100 pig producers and dairies worldwide, solidifying its position as a key player in the animal genetics market[1].

Market Position and Financial Performance

Market Capitalization and Growth

As of January 15, 2025, Genus has a market capitalization of 935.43 million GBP[7]. This represents significant growth over time:

  • Since January 30, 1998, Genus's market cap has increased by 2,914.56%
  • The compound annual growth rate (CAGR) stands at an impressive 13.46%[7]

This growth trajectory underscores Genus's strong market position and investor confidence in its business model.

Financial Highlights

For the fiscal year 2024, Genus reported several positive financial indicators:

  • Adjusted operating profit increased, with notable growth in Europe (13% increase)*
  • Royalty revenue growth of 9% in Europe*[10]

These figures demonstrate Genus's ability to generate revenue and profit in competitive markets.

Genus's Competitive Advantages

Proprietary Genetic Programs

Genus has invested heavily in proprietary genetic programs, resulting in world-leading products across all its species[1]. This investment in research and development (R&D) is a key differentiator for the company.

Technological Leadership

Genus is recognized as a global leader in several cutting-edge technologies:

  1. Genomics
  2. Gene editing
  3. Sexing technologies[1]

These technological capabilities give Genus a significant edge in the animal genetics market.

Global Supply Chain and Distribution Network

Genus's competitive advantage is further strengthened by:

  • Ownership and control of proprietary lines of breeding animals
  • A robust global supply chain
  • An extensive technical service network
  • A wide-reaching sales and distribution network[10]

This integrated approach allows Genus to maintain quality control and efficiently deliver its products to customers worldwide.

Strategic Initiatives and Future Outlook

Focus on R&D Efficiency

Genus has recently conducted a strategic review of its R&D activities, resulting in:

  • Discontinuation of about one-third of R&D projects
  • A more focused approach aligned with company strategy and business needs
  • Expected £5m of annualized adjusted operating profit benefit from FY25[10]

This strategic realignment demonstrates Genus's commitment to efficient resource allocation and profitability.

Innovative Product Development

Genus continues to innovate, with exciting developments in the pipeline:

  1. PRRSv-resistant pig: Expected FDA approval in the first half of 2024[4]
  2. Sexcel Male Beef: A breakthrough using proprietary sexing technology to produce more male calves for the beef supply chain[10]

These innovations showcase Genus's ability to address industry challenges and create value-added products.

Challenges and Market Dynamics

Volatile Chinese Porcine Market

Genus faces challenges in the Chinese porcine market, including:

  • Continued disease outbreaks
  • A less consolidated industry structure
  • Weak consumer demand[4]

Despite these challenges, Genus remains confident in PIC China's potential for medium-term growth through superior genetics and customer service.

Regulatory Landscape

As a company operating in the biotechnology sector, Genus must navigate complex regulatory environments. The company's success in obtaining approvals, such as the anticipated FDA approval for PRRSv-resistant pigs, is crucial for its growth strategy[4].

Genus's Approach to Sustainability

Genus has positioned itself as a contributor to sustainable food production. The company's technology enables customers to:

  • Produce greater volumes of high-quality animal protein
  • Use fewer inputs such as feed, water, and land[10]

This approach aligns with global trends towards more sustainable and efficient agricultural practices.

"Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors."[10]

Competitive Intelligence Strategies

To maintain its competitive edge, Genus likely employs several competitive intelligence strategies common in the pharmaceutical industry:

  1. Data Gathering: Collecting proprietary and non-proprietary information about competitors and market trends[3]
  2. Analysis: Transforming raw data into actionable insights[3]
  3. Knowledge Management: Efficiently storing, organizing, and retrieving data to support decision-making[3]
  4. Patent Landscape Assessment: Monitoring competitors' patent portfolios and expiration dates[6]
  5. Regulatory Strategy Analysis: Understanding competitors' approaches to clinical trials, regulatory submissions, and market access[6]

These strategies allow Genus to stay ahead of industry trends and make informed decisions about product development and market expansion.

Genus in the Context of the Broader Pharmaceutical Industry

While Genus operates in a specialized niche within the pharmaceutical industry, its approach to innovation and market leadership offers valuable insights for the broader sector:

Focused Innovation

Genus's success demonstrates the value of focused innovation in niche markets. By concentrating on animal genetics, the company has become a global leader in its field.

Balancing R&D and Profitability

The company's recent R&D review showcases the importance of balancing innovation with financial performance, a challenge faced by many pharmaceutical companies.

Addressing Global Challenges

Genus's work in developing disease-resistant animals and more efficient breeding techniques aligns with broader pharmaceutical industry efforts to address global health and sustainability challenges.

Key Takeaways

  1. Genus is a global leader in animal genetics, with a strong market position in both porcine and bovine sectors.
  2. The company's competitive advantages include proprietary genetic programs, technological leadership, and a robust global supply chain.
  3. Genus has demonstrated significant market cap growth, with a CAGR of 13.46% since 1998.
  4. Strategic initiatives include focused R&D investments and innovative product development, such as PRRSv-resistant pigs.
  5. The company faces challenges in volatile markets like China but remains confident in its long-term growth potential.
  6. Genus's approach to sustainability aligns with global trends towards more efficient and environmentally friendly food production.
  7. The company's strategies offer valuable insights for the broader pharmaceutical industry, particularly in niche market leadership and balancing innovation with profitability.

FAQs

  1. What are Genus's main product lines? Genus operates through two main brands: ABS for dairy and beef cattle genetics, and PIC for pig genetics.

  2. How does Genus contribute to sustainable food production? Genus's genetic technologies enable farmers to produce more high-quality animal protein while using fewer resources like feed, water, and land.

  3. What is the significance of Genus's PRRSv-resistant pig? The PRRSv-resistant pig is a major innovation expected to receive FDA approval in 2024, potentially revolutionizing pig farming by increasing disease resistance.

  4. How does Genus maintain its competitive edge in the market? Genus maintains its edge through proprietary genetic programs, technological leadership in areas like genomics and gene editing, and a global supply chain and distribution network.

  5. What challenges does Genus face in the Chinese market? Genus faces challenges in China due to disease outbreaks, a less consolidated industry structure, and weak consumer demand. However, the company remains optimistic about long-term growth potential in this market.

Sources cited: [1] https://www.genusplc.com/about-us/our-market/ [3] https://visualping.io/blog/competitive-intelligence-in-pharma [4] https://www.businesswire.com/news/home/20230906828945/en/Genus-plc-Preliminary-Results-for-the-Year-Ended-30-June-2023 [6] https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/ [7] https://stockanalysis.com/quote/lon/GNS/market-cap/ [10] https://www.genusplc.com/media/2151/preliminary-results-fy24-final.pdf

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.